INVIDON-35 XR Tablets
Total Freedom from heart pain
Composition: Trimetazidine HCI B.P. 35 mg (Modified Release)
- Possesses a direct anti-ischemic effect on myocardium & stimulates the coronary blood flow.
- Significantly improves myocardial glucose utilization through inhibition of fatty acid oxidation.
- Well-tolerated and safe drug for patients with diabetic myocardiopathy.
- Profound cytoprotective action during ischemia.
Indication:
- Angina pectoris
Trimetazidine HCl
- Class of medications: Partial fatty acid oxidation inhibitors (so-called PFox inhibitors)
- Trimetazidine hydrochloride is an aromatic amine.
- Efficient cytoprotective anti-anginal drug that exerts anti-ischemic activity.¹
- Safely increases exercise capacity, and decreases the anginal incidence and left-ventricular (LV) dysfunction.²
- Provides long-term cardioprotection by hydroionic balancing and coronary microcirculation.3
- Shows 63% reduction in angina crisis as compared to isosorbide mononitrate.4
REFERENCE
- Indian J Pharm Sci. 2010 Nov-Dec; 72(6): 704-709
- Expert Opin Premacother 2001 May;2(5):857-75
- 2005 Feb; 91(2): 161-165
- Ann Cardiol Angeiol (Paris). 2002 Nov;51(5):268-74